Compare Quest Diagnostics Inc (DGX) vs Nasdaq100 ETF (QQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Nasdaq100 ETF — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while Nasdaq100 ETF trades at $751.19 (market cap $506.92B). The key difference: Nasdaq100 ETF is far larger — about 19.9× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Nasdaq100 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Nasdaq100 ETF for 162 Days on average.
| DGX | QQQ | |
|---|---|---|
Market Cap | $25.48B | $506.92B |
Volume | 941,866 | 48,326,518 |
Sector | Health | — |
52-Week High | $247.45 | $759.66 |
52-Week Low | $173.49 | $558.34 |
Typical Hold Time | 56 Days | 162 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
QQQ trades at $751.27, down 0.85% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF shows strong institutional interest but faces mixed analyst sentiment with a 50% buy and 50% sell rating. Recent news highlights ongoing comparisons with lower-fee alternatives like QQQM and VOO, while AI-driven tech exposure remains a key growth driver amid market volatility concerns.
The outlook for QQQ hinges on tech sector performance and interest rate sensitivity. Opportunities include AI innovation and Nasdaq 100 leadership, but risks involve high concentration in tech stocks, valuation pressures, and macroeconomic headwinds. Investor sentiment is divided, reflecting the ETF's growth potential against fee competitiveness and market cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →
